JWHolding

R&D

WE WILL MAKE HEADWAY INTO THE GLOBAL MARKET BEYOND THE DOMESTIC MARKET BY GATHERING THE ABILITY OF JW

R&D
Open Innovation

Open Innovation

Science & Innovation R&D Nutrition therapy R&D Diagnostics R&D

  • Dec, 2019

    Signing a MOU for “the development of a sepsis patient monitoring system using AI and WRS biomarker”

    • Develop new diagnostic technology using artificial intelligence and WRS biomarkers through global research and development collaboration

    • International Consortium, (South Korea) JW Bioscience, Daegu-Gyeongbuk Medical Innovation Foundation, (Austria) Symptoma GmbH
    • Eureka Network Project, Network Projects are market-driven innovative R&D projects, devised and run by an international consortium.

  • Mar, 2018

    Technology transfer to JW holdings from Yonsei University. (Biomarker for pancreatic cancer diagnosis)

    • Joint research with Yonsei Proteome research center, Yonsei University (Professor Baek Yunggi)
    • Joint research with Clinical statistics analysts of Harvard University
    • Patent are granted (Japan (Jul. 2018) / China (Jan. 2019) / Europe (Jun. 2019) / US (Jan. 2020))of early diagnosis technology of pancreatic cancer.
    • Presented in special sessions of Human Proteome Organization, HUPO(Sep, 2019)


    • Yonsei Proteome research center

    • Asia's first proteome research institute (established in 1999), selected as one of the world's top 10 research institutes (official data for 2009)

  • May, 2016

    Technology transfer to JW Bioscience from Medicinal Bioconvergence research center (Biocon), Seoul national University (Sepsis Biomarker)

    • Clinical research conducted by St. Mary's Hospital(Seoul) and Severance Hospital(Sinchon)
    • Joint development of new POCT(point of care testing) immunoassay analyzer for biomarker measurement (will be released in 2020)
    • Medicinal Bioconvergence Research center (Biocon)

    • Established as one of the Global Frontier projects by the Ministry of science, ICT and future planning
    • Aiming world’s first and best target factory that systematically translate original science and technology to new therapy and diagnosis for future medicinal
Top